ANDREW N SCHIFF
CIK 1172252 · last filed 2026-06-12
ANDREW N SCHIFF is a corporate insider who has filed 44 SEC Form 4 insider transactions across 9 companies since 2008. The most recent filing, for GLUE, was dated Jun 12, 2026. Across all open-market trades the lifetime net is +$8.6M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $2.5M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$2.45M
9
44
$8.59M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| GLUE | Director | — | $22.04 | — | $0 | 6 | 2026-06-12 |
| ACRS | Director | 459,995 | $5.33 | $2.45M | -$1.15M | 19 | 2026-06-08 |
| Elevation Oncology, Inc. (ELEV) Delisted | — | $0.36 | — | $0 | 1 | 2021-06-28 | |
| Zosano Pharma Corp (ZSAN) Delisted | 10%+ Owner | 77,664 | $0.56 | $43.3K | $0 | 2 | 2019-12-06 |
| Viracta Therapeutics, Inc. (SNSS) Delisted | 10%+ Owner | 2,885,714 | $18.62 | $53.73M | $7.50M | 1 | 2019-07-15 |
| Zeltiq Aesthetics Inc (ZLTQ) Delisted | Director | 0 | — | — | -$35.35M | 11 | 2017-05-01 |
| AGILE THERAPEUTICS INC (AGRX) Delisted | Director | — | $1.51 | — | $0 | 1 | 2015-06-10 |
| Loxo Oncology, Inc. (LOXO) Delisted | 10%+ Owner | 3,452,493 | — | — | $37.59M | 1 | 2014-08-06 |
| INTERPHARM HOLDINGS INC (IPA) Delisted | 10%+ Owner | — | $2.07 | — | $0 | 1 | 2008-03-03 |
Recent Filings
44 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-12 | GLUE | Grant (A) | — | $0 | EDGAR |
| 2026-06-08 | ACRS | Mixed | +11,580 | $0 | EDGAR |
| 2025-06-16 | GLUE | Grant (A) | — | $0 | EDGAR |
| 2025-06-09 | ACRS | Mixed | +4,793 | $0 | EDGAR |
| 2024-06-13 | GLUE | Grant (A) | — | $0 | EDGAR |
| 2024-06-10 | ACRS | Grant (A) | — | $0 | EDGAR |
| 2024-06-04 | ACRS | Exer (M) | +4,660 | $0 | EDGAR |
| 2023-06-15 | GLUE | Grant (A) | — | $0 | EDGAR |
| 2023-06-05 | ACRS | Mixed | +4,507 | $0 | EDGAR |
| 2022-11-14 | ACRS | Sell (S) | −53,926 | -$919.6K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.